CAMBRIDGE, Mass., April 7, 2026
Nuvalent, Inc. has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for neladalkib, an investigational ALK-selective inhibitor targeting advanced ALK-positive non-small cell lung cancer (NSCLC) in patients previously treated with tyrosine kinase inhibitors (TKIs). This milestone represents a critical advancement in oncology drug development, highlighting the potential of next-generation targeted therapies to address resistance and improve patient outcomes.
NDA Submission Marks Key Regulatory Milestone
The NDA submission is based on data from the global ALKOVE-1 Phase 1/2 clinical trial, a registration-directed study evaluating neladalkib in patients with advanced ALK-positive NSCLC who have previously received TKI therapy. The trial demonstrated encouraging clinical activity, including intracranial responses and a well-tolerated safety profile, supporting its potential as a new treatment option in this difficult-to-treat patient population.
The rapid progression of neladalkib from initial clinical development to NDA submission in under four years underscores the accelerated pace of innovation in precision oncology. Regulatory designations, including Breakthrough Therapy Designation and Orphan Drug Designation, further emphasize the therapy’s potential to address significant unmet medical needs and enable expedited regulatory review.
Targeted ALK Inhibitor Designed to Overcome Resistance
Advertisement
Neladalkib is a brain-penetrant, highly selective ALK inhibitor engineered to overcome limitations associated with earlier generations of ALK-targeted therapies. The drug is designed to remain active against tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including those with complex mutation profiles such as G1202R.
A key differentiator of neladalkib is its TRK-sparing design, which aims to reduce central nervous system (CNS)-related adverse effects commonly observed with dual ALK/TRK inhibitors. This feature enhances its safety profile while maintaining efficacy, particularly in patients with brain metastases, a common and challenging complication in advanced lung cancer.
By combining target specificity, CNS penetration, and resistance coverage, neladalkib represents a next-generation precision therapy that could deliver durable clinical responses across multiple lines of treatment.
Advancing Precision Oncology and Clinical Innovation
Nuvalent continues to advance a robust pipeline of targeted cancer therapies, leveraging its expertise in structure-based drug design and kinase biology. The company’s focus on overcoming drug resistance and minimizing adverse effects reflects a broader industry trend toward precision medicine and personalized oncology treatments.
The ALKOVE-1 trial remains ongoing, with global enrollment continuing for additional patient populations, including those with other ALK-positive tumors. This ongoing research highlights the expanding potential of neladalkib beyond NSCLC, positioning it as a versatile therapeutic candidate in oncology.
The NDA submission also signals Nuvalent’s readiness to engage closely with regulatory authorities, with the goal of bringing innovative therapies to patients faster while maintaining rigorous safety and efficacy standards.
Nuvalent’s NDA submission for neladalkib marks a significant milestone in the development of targeted therapies for ALK-positive NSCLC, offering hope for patients who have exhausted existing treatment options. With its innovative design, strong clinical data, and regulatory support, neladalkib has the potential to become a new standard of care in precision oncology, reinforcing the importance of continued innovation in cancer treatment.
Source: Nuvalent press release
